Mark Taylor

Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

David Adams, Ivailo Tournev, Mark Taylor et al. · Amyloid · 2022 · 379 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

Mathew S. Maurer, Parag Kale, Marianna Fontana et al. · New England Journal of Medicine · 2023 · 307 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +7

Rituximab in refractory nephrotic syndrome

Kazumoto Iijima, Koichi Kamei, Denis Geary et al. · Pediatric Nephrology · 2009 · 161 citations

Medicine, Nephrology, Pharmacotherapy +10

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Iα inhibit NO-induced cerebral dilation

Wolfgang R. Dostmann, Mark Taylor, Christian K. Nickl et al. · Proceedings of the National Academy of Sciences · 2000 · 151 citations · Full text

Life Sciences, Biochemistry, Pharmacology +16